دورية أكاديمية
Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapy.
| العنوان: | Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapy. |
|---|---|
| المؤلفون: | Stalman EW; Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam UMC, location AMC, University of Amsterdam, Amsterdam, The Netherlands. Electronic address: e.w.stalman@amsterdamumc.nl., Wieske L; Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam UMC, location AMC, University of Amsterdam, Amsterdam, The Netherlands; Department of Clinical Neurophysiology, St Antonius Hospital, Nieuwegein, The Netherlands., Keijser JBD; Department of Immunopathology, Sanquin Research, and Landsteiner Laboratory, Amsterdam UMC, Amsterdam, The Netherlands., van Dam KPJ; Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam UMC, location AMC, University of Amsterdam, Amsterdam, The Netherlands., Kummer LYL; Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam UMC, location AMC, University of Amsterdam, Amsterdam, The Netherlands; Department of Immunopathology, Sanquin Research, and Landsteiner Laboratory, Amsterdam UMC, Amsterdam, The Netherlands., Wilbrink MF; Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam UMC, location AMC, University of Amsterdam, Amsterdam, The Netherlands., van Kempen ZLE; Department of Neurology, Amsterdam UMC, VU University Medical Center, Amsterdam, The Netherlands., Killestein J; Department of Neurology, Amsterdam UMC, VU University Medical Center, Amsterdam, The Netherlands., Volkers AG; Department of Gastroenterology and Hepatology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands., Tas SW; Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, Department of Rheumatology and Clinical Immunology, University of Amsterdam, Amsterdam, The Netherlands., Boekel L; Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, Department of Rheumatology and Clinical Immunology, University of Amsterdam, Amsterdam, The Netherlands., Wolbink GJ; Amsterdam Rheumatology and Immunology Center, location Reade, Department of Rheumatology, Amsterdam, The Netherlands., van der Kooi AJ; Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam UMC, location AMC, University of Amsterdam, Amsterdam, The Netherlands., Raaphorst J; Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam UMC, location AMC, University of Amsterdam, Amsterdam, The Netherlands., Löwenberg M; Department of Gastroenterology and Hepatology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands., Takkenberg RB; Department of Gastroenterology and Hepatology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands., D'Haens GRAM; Department of Gastroenterology and Hepatology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands., Spuls PI; Department of Dermatology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands., Bekkenk MW; Department of Dermatology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands., Musters AH; Department of Dermatology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands., Post NF; Department of Dermatology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands., Bosma AL; Department of Dermatology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands., Hilhorst ML; Department of Internal Medicine, Section of Nephrology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands., Vegting Y; Department of Internal Medicine, Section of Nephrology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands., Bemelman FJ; Department of Internal Medicine, Section of Nephrology, Amsterdam UMC, location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands., Voskuyl AE; Department of Rheumatology and Clinical Immunology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, The Netherlands., Broens B; Department of Rheumatology and Clinical Immunology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, The Netherlands., Parra Sanchez A; Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, Department of Rheumatology and Clinical Immunology, University of Amsterdam, Amsterdam, The Netherlands; Department of Rheumatology and Clinical Immunology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, The Netherlands., van Els CACM; Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands; Faculty of Veterinary Medicine, Utrecht University Utrecht, Utrecht, The Netherlands., de Wit J; Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands., Rutgers A; Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, The Netherlands., de Leeuw K; Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, The Netherlands., Horváth B; Department of Dermatology, Center for Blistering Diseases, University Medical Center Groningen, University Groningen, Groningen, The Netherlands., Verschuuren JJGM; Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands., Ruiter AM; Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands., van Ouwerkerk L; Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands., van der Woude D; Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands., Allaart RCF; Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands., Onno Teng YK; Centre of Expertise for Lupus-, Vasculitis-, and Complement-Mediated Systemic Diseases, Department of Internal Medicine-Nephrology Section, Leiden University Medical Centre, Leiden, The Netherlands., van Paassen P; Department of Nephrology and Clinical Immunology, Maastricht University Medical Center, Maastricht, The Netherlands., Busch MH; Department of Nephrology and Clinical Immunology, Maastricht University Medical Center, Maastricht, The Netherlands., Brusse E; Department of Neurology, Erasmus MC University Medical Center, Rotterdam, The Netherlands., van Doorn PA; Department of Neurology, Erasmus MC University Medical Center, Rotterdam, The Netherlands., Baars AE; Department of Neurology, Erasmus MC University Medical Center, Rotterdam, The Netherlands., Hijnen D; Department of Dermatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands., Schreurs CRG; Department of Dermatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands., van der Pol WL; Department of Neurology and Neurosurgery, Brain Center UMC Utrecht, Utrecht, The Netherlands., Goedee HS; Department of Neurology and Neurosurgery, Brain Center UMC Utrecht, Utrecht, The Netherlands., Steenhuis M; Department of Immunopathology, Sanquin Research, and Landsteiner Laboratory, Amsterdam UMC, Amsterdam, The Netherlands., Keijzer S; Department of Immunopathology, Sanquin Research, and Landsteiner Laboratory, Amsterdam UMC, Amsterdam, The Netherlands., Cristianawati O; Department of Immunopathology, Sanquin Research, and Landsteiner Laboratory, Amsterdam UMC, Amsterdam, The Netherlands., Brinke AT; Department of Immunopathology, Sanquin Research, and Landsteiner Laboratory, Amsterdam UMC, Amsterdam, The Netherlands., Verstegen NJM; Department of Immunopathology, Sanquin Research, and Landsteiner Laboratory, Amsterdam UMC, Amsterdam, The Netherlands., Zwinderman KAH; Clinical Research Unit, Amsterdam UMC, location AMC, University of Amsterdam, Amsterdam, The Netherlands., van Ham SM; Department of Immunopathology, Sanquin Research, and Landsteiner Laboratory, Amsterdam UMC, Amsterdam, The Netherlands; Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, The Netherlands., Rispens T; Department of Immunopathology, Sanquin Research, and Landsteiner Laboratory, Amsterdam UMC, Amsterdam, The Netherlands., Welkers MR; Medical Microbiology and Infection Prevention Department, Amsterdam UMC, location AMC, University of Amsterdam, Amsterdam, The Netherlands., Jonges M; Medical Microbiology and Infection Prevention Department, Amsterdam UMC, location AMC, University of Amsterdam, Amsterdam, The Netherlands., Eftimov F; Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam UMC, location AMC, University of Amsterdam, Amsterdam, The Netherlands., Kuijpers TW; Department of Pediatric Immunology, Rheumatology, and Infectious Disease, Amsterdam UMC, location AMC, University of Amsterdam, Amsterdam, The Netherlands. |
| مؤلفون مشاركون: | T2B! immunity against SARS-CoV-2 study group |
| المصدر: | The Journal of allergy and clinical immunology [J Allergy Clin Immunol] 2024 May 17. Date of Electronic Publication: 2024 May 17. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Mosby Country of Publication: United States NLM ID: 1275002 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6825 (Electronic) Linking ISSN: 00916749 NLM ISO Abbreviation: J Allergy Clin Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: St Louis, Mosby. |
| مستخلص: | Background: Despite impaired humoral response in patients treated with immunosuppressants (ISPs), recent studies found similar severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection compared to controls. One potential explanation is the rapid generation of humoral response on infection, but evidence is lacking. Objectives: We investigated the longitudinal dynamics of the SARS-CoV-2 antibody repertoire after SARS-CoV-2 delta and omicron breakthrough infection in patients with immune-mediated inflammatory diseases (IMIDs) receiving ISP therapy and controls. Methods: As a prospective substudy of the national Target-to-B! (T2B!) consortium, we included IMID patients receiving ISPs therapy and controls who reported SARS-CoV-2 breakthrough infection between July 1, 2021, and April 1, 2022. To get an impression of the dynamics of the antibody repertoire, 3 antibody titers of wild-type RBD, wild-type S, and omicron RBD were measured at 4 time points after SARS-CoV-2 breakthrough infection. Results: We included 302 IMID patients receiving ISPs and 178 controls. Antibody titers increased up to 28 days after breakthrough infection in both groups. However, in IMID patients receiving therapy with anti-CD20 and sphingosine-1 phosphate receptor modulators, antibody titers were considerably lower compared to controls. In the anti-TNF group, we observed slightly lower antibody titers in the early stages and a faster decline of antibodies after infection compared to controls. Breakthrough infections were mostly mild, and hospitalization was required in less than 1% of cases. Conclusions: Most ISPs do not influence the dynamics of the SARS-CoV-2 antibody repertoire and exhibit a rapid recall response with cross-reactive antibody clones toward new virus variants. However, in patients treated with anti-CD20 therapy or sphingosine-1 phosphate receptor modulators, the dynamics were greatly impaired, and to a lesser extent in those who received anti-TNF. Nevertheless, only a few severe breakthrough cases were reported. (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.) |
| فهرسة مساهمة: | Keywords: SARS-CoV-2; autoimmune disease; breakthrough infection; humoral response; immunosuppressants |
| تواريخ الأحداث: | Date Created: 20240519 Latest Revision: 20240621 |
| رمز التحديث: | 20240621 |
| DOI: | 10.1016/j.jaci.2024.04.031 |
| PMID: | 38763170 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1097-6825 |
|---|---|
| DOI: | 10.1016/j.jaci.2024.04.031 |